198 related articles for article (PubMed ID: 24395652)
21. Role of tissue inhibitors of metalloproteinases (TIMPs) in colorectal carcinoma.
Joo YE; Seo KS; Kim J; Kim HS; Rew JS; Park CS; Kim SJ
J Korean Med Sci; 1999 Aug; 14(4):417-23. PubMed ID: 10485622
[TBL] [Abstract][Full Text] [Related]
22. Serum matrix metalloproteinase 2 and tissue inhibitor of matrix metalloproteinases 2 in esophageal cancer patients.
Groblewska M; Mroczko B; Kozlowski M; Niklinski J; Laudanski J; Szmitkowski M
Folia Histochem Cytobiol; 2012; 50(4):590-8. PubMed ID: 23264224
[TBL] [Abstract][Full Text] [Related]
23. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
[TBL] [Abstract][Full Text] [Related]
24. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, aminoterminal propeptide of procollagen type III, and hyaluronan in sera and tissue of patients with capsular contracture after augmentation with Trilucent breast implants.
Ulrich D; Lichtenegger F; Eblenkamp M; Repper D; Pallua N
Plast Reconstr Surg; 2004 Jul; 114(1):229-36. PubMed ID: 15220598
[TBL] [Abstract][Full Text] [Related]
25. Clinical relevance of MMP-9, MMP-2, TIMP-1 and TIMP-2 in colorectal cancer.
Morán A; Iniesta P; García-Aranda C; De Juan C; Díaz-López A; Sánchez-Pernaute A; Torres AJ; Díaz-Rubio E; Balibrea JL; Benito M
Oncol Rep; 2005 Jan; 13(1):115-20. PubMed ID: 15583811
[TBL] [Abstract][Full Text] [Related]
26. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging.
Baker EA; Bergin FG; Leaper DJ
Br J Surg; 2000 Sep; 87(9):1215-21. PubMed ID: 10971431
[TBL] [Abstract][Full Text] [Related]
27. Tissue and circulating immunoreactive protein for MMP-2 and TIMP-2 in head and neck squamous cell carcinoma--tissue immunoreactivity predicts aggressive clinical course.
Ruokolainen H; Pääkkö P; Turpeenniemi-Hujanen T
Mod Pathol; 2006 Feb; 19(2):208-17. PubMed ID: 16424893
[TBL] [Abstract][Full Text] [Related]
28. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
Ulrich D; Hrynyschyn K; Pallua N
Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
[TBL] [Abstract][Full Text] [Related]
29. Expression of MMP-2, -7, -9, MT1-MMP and TIMP-1 and -2 has no prognostic relevance in patients with advanced epithelial ovarian cancer.
Brun JL; Cortez A; Lesieur B; Uzan S; Rouzier R; Daraï E
Oncol Rep; 2012 Apr; 27(4):1049-57. PubMed ID: 22200690
[TBL] [Abstract][Full Text] [Related]
30. Distinct pattern of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 mRNA expression in human colorectal cancer and liver metastases.
Zeng ZS; Guillem JG
Br J Cancer; 1995 Sep; 72(3):575-82. PubMed ID: 7669564
[TBL] [Abstract][Full Text] [Related]
31. Matrix metalloproteinase-2 and tissue inhibitor of metallo-proteinase-2 in colorectal carcinoma invasion and metastasis.
Li BH; Zhao P; Liu SZ; Yu YM; Han M; Wen JK
World J Gastroenterol; 2005 May; 11(20):3046-50. PubMed ID: 15918187
[TBL] [Abstract][Full Text] [Related]
32. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
[TBL] [Abstract][Full Text] [Related]
33. Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma.
Giannelli G; Bergamini C; Marinosci F; Fransvea E; Quaranta M; Lupo L; Schiraldi O; Antonaci S
Int J Cancer; 2002 Feb; 97(4):425-31. PubMed ID: 11802202
[TBL] [Abstract][Full Text] [Related]
34. Eutopic endometrium and peritoneal, ovarian and bowel endometriotic tissues express a different profile of matrix metalloproteinases-2, -3 and -11, and of tissue inhibitor metalloproteinases-1 and -2.
Uzan C; Cortez A; Dufournet C; Fauvet R; Siffroi JP; Daraï E
Virchows Arch; 2004 Dec; 445(6):603-9. PubMed ID: 15452706
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage IB cervical cancer.
Moser PL; Kieback DG; Hefler L; Tempfer C; Neunteufel W; Gitsch G
Anticancer Res; 1999; 19(5C):4391-3. PubMed ID: 10650781
[TBL] [Abstract][Full Text] [Related]
36. Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer--a predictor of tumour stage.
Ring P; Johansson K; Höyhtyä M; Rubin K; Lindmark G
Br J Cancer; 1997; 76(6):805-11. PubMed ID: 9310250
[TBL] [Abstract][Full Text] [Related]
37. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic values of MMP-7, MMP-9, MMP-11, TIMP-1, TIMP-2, CEA, and CA19-9 in patients with colorectal cancer.
Huang X; Lan Y; Li E; Li J; Deng Q; Deng X
J Int Med Res; 2021 May; 49(5):3000605211012570. PubMed ID: 33942633
[TBL] [Abstract][Full Text] [Related]
39. Concentration of metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in the serum of patients with benign and malignant thyroid tumours treated surgically.
Pasieka Z; Stepien H; Czyz W; Pomorski L; Kuzdak K
Endocr Regul; 2004 Jun; 38(2):57-63. PubMed ID: 15497929
[TBL] [Abstract][Full Text] [Related]
40. [Expression of matrix metalloproteinase-2, 9 and it's tissue inhibitor-1, 2 in endometrial carcinoma].
Guo W; Chen G; Zhu C; Wang H
Zhonghua Fu Chan Ke Za Zhi; 2002 Oct; 37(10):604-7. PubMed ID: 12487935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
